局部晚期喉鳞状细胞癌根治性放疗与全喉切除术后辅助放疗的疗效比较:转诊癌症中心的真实世界经验
回顾性纳入2007至2020年连续治疗的100例原发性局部晚期喉鳞状细胞癌患者,比较根治性放疗(64例)与全喉切除术后辅助放疗(36例)的生存结局。根治性放疗组与辅助放疗组的中位总生存分别为100个月与未达到(P=0.506),中位无病生存分别为20个月与未达到(P=0.148);在T4患者中两组结局亦无显著差异。作者认为根治性放疗的结局不劣于全喉切除术后辅助放疗。
要点
- 根治性放疗组与辅助放疗组的中位总生存分别为100个月与未达到,log-rank P=0.506。
- 根治性放疗组与辅助放疗组的中位无病生存分别为20个月与未达到,log-rank P=0.148。
- T4患者中根治性放疗组与辅助放疗组的中位无病生存分别为12个月与36个月,log-rank P=0.868。
核心结论
- 作者分析提示,喉癌根治性放疗的结局不劣于全喉切除术后辅助放疗。
- 在T4患者中,作者认为该发现可使临床医生和患者对根治性放疗作为一种治疗选择感到安心。
研究设计与样本
- 回顾性评估2007年至2020年连续治疗的100例原发性局部晚期喉鳞状细胞癌患者,其中根治性放疗组64例、辅助放疗组36例,中位随访29个月。
主要发现
- 全部患者中,根治性放疗组与辅助放疗组的中位总生存分别为100个月(95%CI=46.5-153.5)与未达到(log-rank P=0.506)。
- 全部患者中,根治性放疗组与辅助放疗组的中位无病生存分别为20个月(95%CI=7.7-32.3)与未达到(log-rank P=0.148)。
- 全部患者3年总生存率在根治性放疗组为64%(95%CI:48-78),在辅助放疗组为75%(95%CI:55-95);3年无病生存率在根治性放疗组为43%(95%CI:29-57),在辅助放疗组为61%(95%CI:41-81)。
- T4患者中,根治性放疗组与辅助放疗组的中位总生存分别为未达到与48个月(95%CI=0-105.3,log-rank P=0.788);中位无病生存分别为12个月(95%CI=9.34-14.65)与36个月(95%CI=4.4-67.5,log-rank P=0.868)。
- T4患者3年总生存率在根治性放疗组为71%(95%CI:42-100),在辅助放疗组为75%(95%CI:50-100);3年无病生存率在根治性放疗组为40%(95%CI:21-79),在辅助放疗组为56%(95%CI:25-87)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laryngeal cancer is a common head and neck cancer. Surgical treatment can impair patients' voice and swallowing function, making definitive radiotherapy a viable alternative for locally advanced cases. METHODS: To compare the outcomes of definitive versus adjuvant radiotherapy in patients with primary locally advanced laryngeal cancer, we retrospectively evaluated consecutive patients treated from 2007 to 2020. We assessed and compared the median and 3-year overall survival (OS), disease-free survival (DFS), distant metastasis control (DMC), and local recurrence-free survival (LRC) in all patients and in T4 patients exclusively. RESULTS: One hundred patients were studied, including definitive (N = 64) and adjuvant (N = 36) radiotherapy. The median follow-up was 29 months. Overall, the median OS in the definitive vs. adjuvant group was 100 months (95%CI = 46.5-153.5) vs. not reached, respectively (log-rank P = 0.506). The median DFS in the definitive vs. adjuvant group was 20 months (95%CI = 7.7-32.3) vs. not reached, respectively (log-rank P = 0.148). Three-year OS and DFS rates in all patients were 64% (95%CI: 48-78) vs. 75% (95%CI: 55-95) and 43% (95%CI:29-57) vs. 61% (95%CI: 41-81) in the definitive vs. adjuvant groups, respectively. Among T4 patients, the median OS in the definitive RT group vs. adjuvant group was not reached vs. 48 (95%CI = 0-105.3), respectively (log-rank P = 0.788). The median DFS in the definitive RT group vs. adjuvant group was 12 months (95%CI = 9.34-14.65) vs. 36 months (95%CI = 4.4-67.5), respectively (log-rank P = 0.868). Three-year OS and DFS rates were 71% (95%CI: 42-100) vs. 75% (95%CI: 50-100) and 40% (95%CI:21-79) vs. 56% (95%CI: 25-87) in the definitive vs. adjuvant groups, respectively. CONCLUSIONS: Our analysis suggests that definitive radiotherapy in laryngeal cancer does not lead to a poorer outcome than total laryngectomy followed by adjuvant radiotherapy. In T4 patients, our findings should reassure clinicians and patients about the viability of definitive radiotherapy as a treatment approach.
引用
- Kazemian A, Esmati E, Ghalehtaki R, et al. Outcomes of definitive radiotherapy vs. laryngectomy followed by adjuvant radiotherapy in patients with locally advanced laryngeal squamous cell carcinoma: real-world experience in a referral cancer center. Radiat Oncol. 2024. PMID: 39696417. doi:10.1186/s13014-024-02565-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。